Sara Selitsky, PhD

Founder and CEO

Sara is an experienced bioinformatician with more than 10 years of experience and 8 years of consulting experience. Her research focused on analytics and tool development for genomics of cancer and immunology. She received her PhD in Bioinformatics from the University of North Carolina and after graduation joined the Bioinformatics Core in the cancer center at UNC where she became an Assistant Professor. Next, she joined a data-generation company as a Senior Bioinformatics Scientist. In 2020, Sara left to focus full-time on growing QuantBio.


Vincent Perez, PhD

Bioinformatics Scientist

Prior to his work at QuantBio, Vincent worked at the University of North Carolina at Chapel Hill in a translational oncology research lab alongside UNC’s surgical oncology team. Currently, Vincent’s oncology experience is focused on the stroma of the microenvironment utilizing pan-cancer analyses. Together, he has over 6 years of bioinformatics experience in oncology-focused research and 4 years of wet lab experimentation and design in animal/cell models. Dr. Perez provides bioinformatics expertise in single-cell RNA-sequencing analyses (both droplet and plate-based platforms), bulk RNA-sequencing (short and long-read), microarray, proteomics, integrative -omics analysis, and copy number variation calling.


Rosa Hernansaiz-Ballesteros, PhD

Senior Bioinformatics Consultant

Dr. Hernansaiz-Ballesteros is a biotechnologist by training with more than 9 years of experience in bioinformatics and computational biology. Starting at the end of her bachelor and throughout her masters, she developed and applied systems biology approaches to identify the impact of genomic variants in individual patients. Funded by Microsoft Research, she pursued her PhD focused on dynamic modeling of the cell cycle’s regulation. In 2018, she received her PhD in computational biology from King's College London (UK).

Prior to joining QuantBio, Dr. Hernansaiz-Ballesteros worked at Heidelberg University (Germany) as part of the European Project individualizePeaediatricCure (IPC), which aimed to address effective personalized medicine for children with cancer through computational approaches.